ERBB2 and breast cancer: Moreover, using the “activated-d16HER2 metagene” to examine 2 datasets of HER2-positive BC patients who had been treated with trastuzumab-based neoadjuvant therapy or not, this metagene was more highly expressed in patients who achieved a complete or near-complete response to trastuzumab than in partial responders.